Select Medical Reports Revenue Beat, Stock Price Drops Despite Healthcare Trends
Outpatient and specialty care stocks delivered a mixed Q3 performance, revealing challenges and opportunities within the sector. The industry, characterized by its focus on targeted medical services in non-hospital settings—often viewed as cost-effective alternatives to inpatient care—continues to navigate a complex landscape shaped by evolving healthcare trends and regulatory pressures. This sector’s stability stems from the recurring nature of treatments for chronic conditions and the development of enduring patient relationships. However, significant risks remain, notably reliance on government reimbursement programs like Medicare and the substantial capital investment required to scale operations amidst growing competition from larger, integrated healthcare systems. Looking forward, the industry’s growth prospects are bolstered by increasing demand for outpatient services, driven by an aging population, a rising prevalence of chronic diseases, and the shift toward value-based care models. Technological advancements—including sophisticated medical devices and the integration of data and artificial intelligence—are further supporting the expansion of complex procedures within outpatient settings and promoting preventative care strategies. Despite these tailwinds, headwinds such as reimbursement rate cuts, ongoing labor shortages, and the financial burdens associated with digital transformation present considerable challenges.
Several key outpatient and specialty care providers reported their Q3 results, yielding varied outcomes. Select Medical (NYSE:SEM) demonstrated a robust quarter, generating revenues of $1.36 billion, representing a 7.2% year-over-year increase. This exceeded analyst expectations by 2.7%, solidifying its position as a leader within the sector. The company operates a nationwide network spanning 46 states and over 2,700 healthcare facilities, specializing in critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers. While the stock experienced a notable 9.6% decline since reporting due to investor expectations exceeding Wall Street’s projections, the company’s strong performance highlighted its ability to capitalize on key trends.
U.S. Physical Therapy (NYSE:USPH) showcased the fastest revenue growth among its peers, achieving a 17.3% year-over-year revenue increase to $197.1 million. This performance, exceeding analyst expectations by 1%, reflected the company’s ability to attract new patients and expand its service offerings. However, the stock’s 22.4% decline since reporting underscored investor concerns, particularly given revenue growth outpacing Wall Street estimates. The company operates a nationwide footprint encompassing 671 clinics across 42 states and offers outpatient physical therapy services alongside industrial injury prevention solutions for employers.
DaVita (NYSE:DVA) presented the weakest performance within the group, with revenues reaching $3.42 billion, a 4.8% year-over-year increase. While this aligned with analyst expectations, a significant miss of EPS estimates and revenue significantly below forecasts contributed to a 9.1% decline in its stock price. Operating over 2,600 dialysis centers across the United States and internationally (including a presence in 13 countries), DaVita specializes in providing treatment for patients with chronic kidney disease and end-stage kidney disease.
Agilon Health (NYSE:AGL) adopted a value-based care approach, transitioning primary care physicians to value-based care models for Medicare patients through long-term partnerships and global capitation arrangements. Revenues were reported at $1.44 billion, down 1.1% year-over-year, which, after surpassing analysts’ expectations by 1%, did not prevent a 28.8% decline in the stock price. The company added 5,000 customers to reach a total of 503,000.
Surgery Partners (NASDAQ:SGRY) operated over 180 locations across 33 states serving as alternatives to traditional hospital settings, generating $821.5 million in revenue—a 6.6% year-over-year increase. This number met analyst expectations and aligned with a significant miss of EPS estimates and full-year revenue guidance, generating a 27.2% drop in the stock price.
The overall market environment continues to reflect a softening of inflation following the Fed’s rate hikes in 2022 and 2023. While inflationary pressures have subsided from their peak levels post-pandemic, the rise in the price of goods and services aligns with the Fed’s 2% goal. Furthermore, the Fed’s rate adjustments—including half a percent in September and a quarter percent in November 2024—have avoided triggering a recession. However, uncertainties remain surrounding the economic outlook and potential tariff impacts—as well as corporate tax cuts—present ongoing challenges. This backdrop fueled a substantial market rally throughout 2024, culminating in all-time highs in major indices following Donald Trump’s victory in the U.S. Presidential Election. Investment firms are now guiding investors towards companies with strong fundamentals and resilience—such as those showcased in the outpatient and specialty care sector. StockStory’s analysis, driven by quantitative data and automated processes, delivers market-beating insights and helps investors identify opportunities, regardless of the macroeconomic environment.
